PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

BackgroundProstate specific membrane antigen (PSMA) PET imaging has recently gained attention in glioblastoma (GBM) patients as a potential theranostic target for PSMA radioligand therapy. However, PSMA PET has not yet been established in a murine GBM model. Our goal was to investigate the potential...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maximilian A. Kirchner, Adrien Holzgreve, Matthias Brendel, Michael Orth, Viktoria C. Ruf, Katja Steiger, Dennis Pötter, Lukas Gold, Marcus Unterrainer, Lena M. Mittlmeier, Enio Barci, Roland E. Kälin, Rainer Glass, Simon Lindner, Lena Kaiser, Jessica Maas, Louisa von Baumgarten, Harun Ilhan, Claus Belka, Johannes Notni, Peter Bartenstein, Kirsten Lauber, Nathalie L. Albert
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Prostate specific membrane antigen (PSMA)
18F-PSMA-1007 PET
glioblastoma
GL261
preclinical
mouse
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/a33fdca79420480f90602dfda9688c64
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/a33fdca79420480f90602dfda9688c64

Ejemplares similares